Wall Street Analysts Predict AtriCure (ATRC) May Surge 36.3%: Here's How to Invest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 25 2025
0mins
Should l Buy ATRC?
Source: NASDAQ.COM
Stock Performance and Analyst Predictions: AtriCure (ATRC) shares have risen 3.5% recently, with Wall Street analysts projecting a mean price target of $51.44, suggesting a potential upside of 36.3%. The price targets range from $40.00 to $64.00, indicating varying levels of optimism among analysts.
Skepticism Towards Price Targets: While price targets are popular among investors, they can often mislead, as analysts may set overly optimistic targets due to business incentives. A low standard deviation in price targets indicates strong agreement among analysts, but it should not be the sole basis for investment decisions.
Earnings Estimate Revisions: Analysts have shown increased optimism regarding AtriCure's earnings, with a 32.9% rise in the Zacks Consensus Estimate for the current year. This trend in earnings estimate revisions is correlated with potential stock price movements.
Zacks Rank and Investment Outlook: AtriCure holds a Zacks Rank #2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates. This ranking, along with a strong track record, suggests a favorable outlook for the stock despite the skepticism surrounding price targets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATRC?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATRC
Wall Street analysts forecast ATRC stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 29.390
Low
45.00
Averages
52.20
High
64.00
Current: 29.390
Low
45.00
Averages
52.20
High
64.00
About ATRC
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ATRICURE INC: UBS Lowers Price Target to $55 from $60
- Price Adjustment: AtriCure has reduced its target price from $60 to $55.
- Market Impact: This adjustment may reflect changes in market conditions or company performance expectations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Changes in analyst ratings may lead to short-term volatility in the affected stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Impact of Rating Changes: Upgrades typically boost investor confidence and may drive stock prices higher, while downgrades can trigger sell-offs, impacting company valuations, necessitating careful evaluation by investors.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for broader market insights.
See More
AtriCure Reports Strong Q4 2025 Earnings with 15% Revenue Growth
- Significant Revenue Growth: AtriCure reported total revenue of $534 million for 2025, reflecting a 15% increase over 2024, showcasing strong performance across multiple business segments, particularly following new product launches that are expected to further drive future revenue growth.
- Improved Profitability: The company achieved nearly $62 million in adjusted EBITDA and generated $45 million in cash for 2025, indicating a substantial enhancement in profitability and cash flow, which provides financial support for future investments and expansion.
- Clinical Trial Progress: The completion of enrollment in the LeAAPS clinical trial with over 6,500 patients and the initiation of the BoxX-NoAF trial are expected to provide critical data for future product development and market promotion, further solidifying AtriCure's market position.
- Optimistic Outlook: Management projects revenue growth of 12% to 14% for 2026 and reaffirms an adjusted EBITDA target between $80 million and $82 million, reflecting confidence in future growth despite competitive pressures and uncertainties in international markets.
See More
AtriCure Q4 Earnings Exceed Expectations
- Earnings Beat: AtriCure reported a Q4 non-GAAP EPS of $0.06, surpassing expectations by $0.10, indicating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q4 revenue of $140.5 million, reflecting a 13.1% year-over-year increase and exceeding analyst expectations by $0.72 million, showcasing its sustained growth momentum in the cardiac device market.
- Market Reaction: Despite the strong performance, AtriCure's stock slid 15% following a downgrade by JPMorgan, highlighting market concerns over intensified competition, particularly from Edwards.
- Industry Conference Presentation: AtriCure showcased its latest developments at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility and attracting investor interest within the healthcare sector.
See More
AtriCure Shares Plunge After JPMorgan Downgrade
- Downgrade Impact: JPMorgan downgraded AtriCure from Overweight to Neutral, causing shares to plunge by 15% during mid-day trading on Wednesday, indicating market concerns about the company's future performance.
- Price Target Reduction: The brokerage lowered its price target for AtriCure from $48 to $36, reflecting a significant decrease in analysts' expectations for the company's profitability, which may undermine investor confidence.
- Increased Competitive Pressure: The announcement by Edwards Lifesciences to launch a surgical left atrial appendage closure product, which competes with AtriCure's AtriClip, intensifies market competition and poses a threat to AtriCure's market share.
- Changing Market Position: Edwards Lifesciences' leading position in the cardiac surgery market, particularly in surgical valve replacements, could weaken AtriCure's market position in its Open business, further impacting its long-term growth potential.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
ATRICURE INC: UBS Lowers Price Target to $55 from $60
- Price Adjustment: AtriCure has reduced its target price from $60 to $55.
- Market Impact: This adjustment may reflect changes in market conditions or company performance expectations.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Reaction Expectations: Changes in analyst ratings may lead to short-term volatility in the affected stocks, prompting investors to closely monitor these shifts to timely adjust their portfolios for optimized returns.
- Impact of Rating Changes: Upgrades typically boost investor confidence and may drive stock prices higher, while downgrades can trigger sell-offs, impacting company valuations, necessitating careful evaluation by investors.
- Comprehensive Rating View: For a complete overview of all analyst rating changes, including specific upgrades and downgrades, it is recommended to visit the analyst ratings page for broader market insights.
See More
AtriCure Reports Strong Q4 2025 Earnings with 15% Revenue Growth
- Significant Revenue Growth: AtriCure reported total revenue of $534 million for 2025, reflecting a 15% increase over 2024, showcasing strong performance across multiple business segments, particularly following new product launches that are expected to further drive future revenue growth.
- Improved Profitability: The company achieved nearly $62 million in adjusted EBITDA and generated $45 million in cash for 2025, indicating a substantial enhancement in profitability and cash flow, which provides financial support for future investments and expansion.
- Clinical Trial Progress: The completion of enrollment in the LeAAPS clinical trial with over 6,500 patients and the initiation of the BoxX-NoAF trial are expected to provide critical data for future product development and market promotion, further solidifying AtriCure's market position.
- Optimistic Outlook: Management projects revenue growth of 12% to 14% for 2026 and reaffirms an adjusted EBITDA target between $80 million and $82 million, reflecting confidence in future growth despite competitive pressures and uncertainties in international markets.
See More
AtriCure Q4 Earnings Exceed Expectations
- Earnings Beat: AtriCure reported a Q4 non-GAAP EPS of $0.06, surpassing expectations by $0.10, indicating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Growth: The company achieved Q4 revenue of $140.5 million, reflecting a 13.1% year-over-year increase and exceeding analyst expectations by $0.72 million, showcasing its sustained growth momentum in the cardiac device market.
- Market Reaction: Despite the strong performance, AtriCure's stock slid 15% following a downgrade by JPMorgan, highlighting market concerns over intensified competition, particularly from Edwards.
- Industry Conference Presentation: AtriCure showcased its latest developments at the 44th Annual J.P. Morgan Healthcare Conference, enhancing its visibility and attracting investor interest within the healthcare sector.
See More
AtriCure Shares Plunge After JPMorgan Downgrade
- Downgrade Impact: JPMorgan downgraded AtriCure from Overweight to Neutral, causing shares to plunge by 15% during mid-day trading on Wednesday, indicating market concerns about the company's future performance.
- Price Target Reduction: The brokerage lowered its price target for AtriCure from $48 to $36, reflecting a significant decrease in analysts' expectations for the company's profitability, which may undermine investor confidence.
- Increased Competitive Pressure: The announcement by Edwards Lifesciences to launch a surgical left atrial appendage closure product, which competes with AtriCure's AtriClip, intensifies market competition and poses a threat to AtriCure's market share.
- Changing Market Position: Edwards Lifesciences' leading position in the cardiac surgery market, particularly in surgical valve replacements, could weaken AtriCure's market position in its Open business, further impacting its long-term growth potential.
See More
Elekta EKTAY's Evo CT-Linac Receives FDA Clearance, Enhancing Personalized Radiation Therapy
- FDA Approval Milestone: Elekta's Evo CT-Linac has received 510(k) clearance from the FDA, enabling its availability in the U.S. market, marking a critical step in the company's expansion in radiation oncology and expected to drive the adoption of personalized radiation therapy.
- Market Growth Potential: The AI-driven imaging capabilities of Elekta Evo enhance the visualization of tumors and organs-at-risk, which is anticipated to drive revenue growth and deepen customer relationships, further solidifying the company's position in the competitive radiation therapy market.
- Operational Efficiency Improvement: Elekta is implementing a new operating model expected to generate annual cost savings of at least SEK 500 million, aimed at accelerating product development and improving overall operational efficiency, thereby enhancing customer service quality.
- Order Review Impact: Elekta has completed a second-level review of orders, resulting in the cancellation of approximately SEK 2.197 billion in orders to improve predictability and support long-term profitability, reflecting the company's stringent control over order criteria.
See More
